FI

Firefly

3 known investors

fireflybiologics.com ↗

Firefly Bio develops Degrader Antibody Conjugates (DACs), a technology that combines antibody drug conjugates with selective protein degraders to deliver degraders to target tissue. The company operates in oncology drug development and was acquired by Johnson & Johnson.

Investors · 3

DE

Decheng CapitalMenlo Park

MP

MPM BioImpactBoston · $1M – $15M

MP

MPM Capital